Tuesday, May 24

Covid-19. Messenger RNA vaccines do not increase cardiovascular risk in people under 75

Messenger RNA vaccines against Covid-19 do not increase the risk of serious cardiovascular problems (heart attack, stroke or pulmonary embolism) in people under 75, underlines Tuesday a study published by the Medicines Agency.

As part of the enhanced vaccine monitoring system, Epi-Phare, a structure associating Health Insurance (Cnam) and the Medicines Agency (ANSM), conducted a study on the risk of serious cardiovascular event (excluding myocarditis and pericarditis) within three weeks of injection of an mRNA or adenovirus vaccine. This study focused on all adults aged 18 to 74, vaccinated or not, admitted to hospital in France between December 27, 2020 and July 20, 2021 for acute myocardial infarction, ischemic stroke or haemorrhagic, or pulmonary embolism.

“Major result”, which confirms the safety of Pfizer and Moderna

The results confirm the “safety of mRNA vaccines” (those from Pfizer and Moderna) “with respect to the risk of a serious cardiovascular event in adults” which could have occurred during the three weeks following the first or second doses of vaccines.

“For us, this is a major result which confirms the safety of messenger RNA vaccines in people under 75,” commented Rosemary Dray-Spira, epidemiologist and deputy director of the Epi-Phare structure.

This content is blocked because you did not accept trackers.

Clicking on ” I accept “, the tracers will be deposited and you will be able to view the contents .

Clicking on “I accept all trackers”, you authorize deposits of tracers for the storage of your data on our sites and applications for the purposes of personalization and advertising targeting.

You retain the option to withdraw your consent at any time.
Manage my choices

“Light” risk with AstraZeneca and Janssen

On the other hand, adenovirus vaccines (those from AstraZeneca and Janssen) appear “associated with a slight increase in the risk of myocardial infarction and pulmonary embolism in adults, within two weeks of injection”. These adenovirus vaccines are little used in France, recalls the ANSM.

Similar results in people over 75

The results of this survey corroborate those of other international studies. A previous study, which focused on people aged 75 or over, had not shown an increase in cardiovascular risk after each of the two doses of the Pfizer vaccine.


Leave a Reply

Your email address will not be published.